Characteristics of Japanese Duchenne and Becker Muscular Dystrophy Patients in a Novel Japanese National Registry of Muscular Dystrophy (Remudy)

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Specialty General Medicine

Date 2013 Apr 23

PMID 23601510

Citations 30

Authors

Harumasa Nakamura

En Kimura

Madoka Mori-Yoshimura

Hirofumi Komaki

Yu Matsuda

Kanako Goto

Yukiko K Hayashi

Ichizo Nishino

Shinichi Takeda

Mitsuru Kawai

Affiliations

Soon will be listed here.

Abstract

Background: Currently, clinical trials for new therapeutic strategies are being planned for Duchenne and Becker muscular dystrophies (DMD/BMD). However, it is difficult to obtain adequate numbers of patients in clinical trials. As solutions to these problems, patient registries are an important resource worldwide, especially in rare diseases such as DMD/BMD.

Methods: We developed a national registry of Japanese DMD/BMD patients in collaboration with TREAT-NMD. The registry includes male Japanese DMD/BMD patients whose genetic status has been confirmed by genetic analysis. The registry includes patients throughout Japan.

Results: As of February 2012, 583 DMD and 105 BMD patients were registered. Most individuals aged less than 20 years. In terms of genetic mutations of registrants of DMD and BMD, deletion of exons was the most frequent (61.4% and 79.0%) followed by point mutations (24.5% and 14.3%) and duplications (13.6% and 4.8%), respectively. 43.6% of DMD are capable of walking, and 76.2% of BMD registrants are able to walk. 41.1% of DMD registrants in the database were treated using steroids. 29.5% of DMD and 23.8% of BMD registrants were prescribed one cardiac medicine at least. 22% of DMD used ventilator support, and non-invasive support was common. Small numbers of DMD and BMD registrants, only 3.9% and 1.0% of them, have received scoliosis surgery. 57 (9.8%) patients were eligible to clinical trial focused on 'skipping' exon 51.

Conclusions: The Remudy has already demonstrated utility in clinical researches and standardization of patients care for DMD/BMD. This new DMD/BMD patient registry facilitates the synchronization of clinical drug development in Japan with that in other countries.

Citing Articles

Clinical Profile and Pulmonary Function of Pediatric Patients with Duchenne Muscular Dystrophy at a Tertiary Government Hospital.

Arquillo M, Layug E, Lozada M, Bautista K, Calotes-Castillo L Acta Med Philipp. 2025; 58(21):49-59.

PMID: 39758300 PMC: 11694038. DOI: 10.47895/amp.vi0.7975.

Comprehensive analysis of 2097 patients with dystrophinopathy based on a database from 2011 to 2021.

Zhao L, Shi Y, Hu C, Zhou S, Li H, Zhang L Orphanet J Rare Dis. 2024; 19(1):311.

PMID: 39182149 PMC: 11344408. DOI: 10.1186/s13023-024-03217-7.

The Dutch Dystrophinopathy Database: A National Registry with Standardized Patient and Clinician Reported Real-World Data.

van de Velde N, Krom Y, Bongers J, Hoek R, Ikelaar N, van der Holst M J Neuromuscul Dis. 2024; 11(5):1095-1109.

PMID: 39031379 PMC: 11380288. DOI: 10.3233/JND-240061.

Social difficulties and care burden of adult Duchenne muscular dystrophy in Japan: a questionnaire survey based on the Japanese Registry of Muscular Dystrophy (Remudy).

Mori-Yoshimura M, Ishigaki K, Shimizu-Motohashi Y, Ishihara N, Unuma A, Yoshida S Orphanet J Rare Dis. 2024; 19(1):182.

PMID: 38689355 PMC: 11061927. DOI: 10.1186/s13023-024-03087-z.

Multidimensional analyses of the pathomechanism caused by the non-catalytic GNE variant, c.620A>T, in patients with GNE myopathy.

Yoshioka W, Iida A, Sonehara K, Yamamoto K, Oya Y, Mori-Yoshimura M Sci Rep. 2022; 12(1):21806.

PMID: 36526893 PMC: 9758176. DOI: 10.1038/s41598-022-26419-0.

References

Guglieri M, Bushby K . Molecular treatments in Duchenne muscular dystrophy. Curr Opin Pharmacol. 2010; 10(3):331-7. DOI: 10.1016/j.coph.2010.03.005. View

Emery A . The muscular dystrophies. Lancet. 2002; 359(9307):687-95. DOI: 10.1016/S0140-6736(02)07815-7. View

van Deutekom J, Janson A, Ginjaar I, Frankhuizen W, Aartsma-Rus A, Bremmer-Bout M . Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007; 357(26):2677-86. DOI: 10.1056/NEJMoa073108. View

Fukunaga H, Ishiduka T, Sato M, Igata A, Nishitani H . [Database for patients with Duchenne muscular dystrophy]. Rinsho Shinkeigaku. 1990; 30(11):1202-7. View

Aartsma-Rus A, van Deutekom J, Fokkema I, van Ommen G, den Dunnen J . Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006; 34(2):135-44. DOI: 10.1002/mus.20586. View

Davies K, Smith T, Bundey S, Read A, Flint T, Bell M . Mild and severe muscular dystrophy associated with deletions in Xp21 of the human X chromosome. J Med Genet. 1988; 25(1):9-13. PMC: 1015414. DOI: 10.1136/jmg.25.1.9. View

Goemans N, Tulinius M, van den Akker J, Burm B, Ekhart P, Heuvelmans N . Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med. 2011; 364(16):1513-22. DOI: 10.1056/NEJMoa1011367. View

van Deutekom J, van Ommen G . Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet. 2003; 4(10):774-83. DOI: 10.1038/nrg1180. View

Thompson R, Schoser B, Monckton D, Blonsky K, Lochmuller H . Patient Registries and Trial Readiness in Myotonic Dystrophy--TREAT-NMD/Marigold International Workshop Report. Neuromuscul Disord. 2009; 19(12):860-6. DOI: 10.1016/j.nmd.2009.08.009. View

10.

Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y . Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet. 2010; 55(6):379-88. DOI: 10.1038/jhg.2010.49. View

11.

Muntoni F, Torelli S, Ferlini A . Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003; 2(12):731-40. DOI: 10.1016/s1474-4422(03)00585-4. View

12.

Ishikawa Y, Miura T, Ishikawa Y, Aoyagi T, Ogata H, Hamada S . Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord. 2010; 21(1):47-51. DOI: 10.1016/j.nmd.2010.09.006. View

13.

Welch E, Barton E, Zhuo J, Tomizawa Y, Friesen W, Trifillis P . PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007; 447(7140):87-91. DOI: 10.1038/nature05756. View

14.

Zhang Y, Wang Y, Li L, Guo J, Wang J . China's first rare-disease registry is under development. Lancet. 2011; 378(9793):769-70. DOI: 10.1016/S0140-6736(11)61375-5. View